A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors
Date: Last Updated 7/6/2018
Regions: US; South; Investigational Site Number 8400003, Dallas, TX, 75230; US; South; Investigational Site 8400006, Nashville, TN, 37203; US; Northeast and Mid-Atlantic; Investigational Site Number 8400001 and Investigational Site Number 8400101, Boston, MA, 02114 and 02115; US; Midwest, Investigational Site Number 8400004, Fairway, KS, 66205
Contact: Trial Transparency email recommended (Toll free number for US & Canada) 800-633-1610 ext 1 then # Contact-Us@sanofi.com
To determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of SAR439459 when administered intravenously as monotherapy in adult patients with advanced solid tumors, et al.
Pembrolizumab in Combination With CRT for LA-SCCHN
Date: Last updated 10/6/2017
Regions: US; Midwest; Sanford-Bismarck Medical Center, Bismarck, ND, 58501 and Sanford-Roger Maris Cancer Center, Fargo, ND, 58122; US; Midwest; Sanford Health Cancer Center, Sioux Falls, SD, 57104; US; West Coast, UCSD Moores Cancer Center, La Jolla, CA 92093
Contact: Sanford-Bismarck Medical Center: Tammy Fischer, RN, 701-323-5365, Tamara.Fischer@sanfordhealth.org; Sanford-Roger Maris Cancer Center: Mary Schuster, RN, 701-234-7514, email@example.com; Sanford Health Cancer Center: Central Referral Line 877-878-4825, SH-MISP@sanfordhealth.org; UCSD Moores Cancer Center: Mandy Natsuhara, 858-534-7613, firstname.lastname@example.org
This is a single-arm, multi-site, open-label trial of pembrolizumab (MK-3475) used in combination with standard, cisplatin-based, definitive chemoradiotherapy (CRT) in patients with stage III-IVB squamous cell carcinoma of the head and neck (SCCHN). Approximately 39 patients with Stage III-IVB SCCHN will be enrolled to evaluate both the safety and efficacy of this novel combination. Subjects will not be randomized and will all receive the study treatment.
Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells
Date: Last updated 6/13/2018
Regions: Asia; China; Hangzhou Cancer Hospital, Hangzhou, Zhejiang, 310002
Contact: Shixiu Wu,+8657186826086, email@example.com
This is a phase I clinical study of expanded NK cells from autologous origin. The NK cell will be selected and expanded ex vivo and infused back into patients. Nimotuzumab will be used 24 hours before infusion. 21 advanced cancer patients are planned to receive two cycles of NK cells and Nimotuzumab treatment. Biomarkers and immunological markers are collected and analyzed as well.
Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer
Trial Identifier: NCT03187314
Date: 6/2017 (last updated 6/2017)
Regions: Asia; China; Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China, 310002 Contact: Shixiu Wu, MD +8657186826086 firstname.lastname@example.org Contact: Zhao Jing, MD +8657156008656 email@example.com
The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 in patients with esophageal cancer
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)
Trial Identifier: NCT03189719
Date: 6/2017 (last updated 6/2017)
Regions: Varied; Contact: Toll Free Number 1-888-577-8839 Trialsites@merck.com, Please refer to this study by its ClinicalTrials.gov identifier: NCT03189719
The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) chemotherapy versus placebo plus cisplatin and 5-FU chemotherapy as first-line treatment in participants with locally advanced or metastatic esophageal carcinoma.
The Study of SHR7390 in Combination With SHR-1210 in Patients With Advanced Solid Tumors
Date: Last updated 2/28/2018
Regions: Asia, China, The Cancer Center, Sun Yat-sen University Guangzhou, Guangdong, 510060
Contact: RuiHua Xu, MD, PhD, 86-20-8734-3008, firstname.lastname@example.org or Yi Liu, PhD, 86-21-6045-3192 ext 822, email@example.com
This aim of study to assess the safety and tolerability of SHR7390 combined with SHR-1210 and to define Dose limiting toxicity（DLT）and the maximum tolerated dose (MTD) of SHR7390 in the patients with advanced solid tumors.
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
Date: Last updated 6/12/2018
Regions: US; South; Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, NC 27599
Contact: Jared Weiss, MD, 919-843-7718, firstname.lastname@example.org
Participants in this study have locally-advanced SCCHN. In this study the investigators are testing the combination of carboplatin, nano-albumin bound paclitaxel and durvalumab. The purpose of this study is to test a combination of chemotherapy to hopefully both increase the number of subjects that respond to therapy while also decreasing the number of side effects that subjects experience.
Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)
Date: Last updated 6/21/2018
Regions: Multiple Sites: USA, Australia, Israel, Japan, Korea; call Merck Trial Finder for site details.
Contact: Toll Free Number: 1-888-577-8839, Trialsites@merck.com
This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of MK-1308 when used in combination with pembrolizumab in participants with advanced solid tumors.
Special Combination of OBP-301 and Pembrolizumab
Trial Identifier: NCT03172819
Date: 5/2017 (last updated 6/2017)
Regions: Asia; Japan; National Cancer Center Hospital East; Kashiwa, Chiba. Contact: Takashi Kojima, Dr +81-4-7133-1111 ext 91266 OBPem_core@east.ncc.go.jp
This is multicenter, open-label Phase I study to exploratively evaluate the efficacy and safety of OBP-301 in combination with Pembrolizumab in patients with advanced solid tumors.
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
Date: Last updated 5/22/2018
Regions: USA; Northeast and Mid-Atlantic; Multiple sites in NY and NJ; Memoral Sloan Kettering Basking Ridge, Basking Ridge, NJ 07920; Memorial Sloan Kettering Monmouth, Middletown, NJ 07748; Memorial Sloan Kettering Commack, Commack, NY 11725; Memorial Sloan Kettering Westchester, Harrison, NY 10604; Memorial Sloan Kettering Cancer Center, New York, NY 10065; Memorial Sloan Kettering Rockville Centre, Rockville Centre, NY 11570
Contact: Alan Ho, MD, PhD, 646-888-4235, email@example.com
The purpose of this study is to find out what effects, good and/or bad, treatment with two drugs called nivolumab and ipilimumab have on the participant and salivary cancer.
Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Trial Identifier: NCT03172936
Date: 5/2017 (last updated 5/2017)
Regions: 1-888-669-6682, Novartis.firstname.lastname@example.org. Please refer to trial identifier NCT03172936.
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.
Oropharyngeal Cancer (HPV+)
Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer
Trial Identifier: NCT03162224
Date: 5/2017 (last updated 5/2017)
Regions: US; Northeast and Mid-Atlantic; Research Site Recruiting The Bronx, New York, United States, 10461; Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 email@example.com, use NCT03162224
This is a Phase 1b/2a, open-label, multi-center study to evaluate the safety and tolerability, anti-tumor activity, and immunogenicity of MEDI0457 (also known as INO 3112) a HPV DNA vaccine in combination with durvalumab (also known as MEDI4736) which is a human monoclonal antibody directed against PD-L1, which blocks the interaction of PD-L1 with PD-1 and CD80.
E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers
Trial Identifier: NCT02858310
Date: 8/2016 (last updated 4/2017)
Regions: US; Northeast and Mid-Atlantic; National Institutes of Health Clinical Center (Bethesda, Maryland)
Background: Human papillomavirus (HPV) can cause cervical, throat, anal, and genital cancers. Cancers caused by HPV have a HPV protein called E7 inside of their cells. In this new therapy, researchers take a person s blood, remove certain white blood cells, and insert genes that make them to target cancer cells that have the E7 protein. The genetically changed cells, called E7 TCR cells, are then given back to the person to fight the cancer. Researchers want to see if this can help people. Objective: To determine a safe dose of E7 TCR cells and whether these cells can help patients.
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
Trial Identifier: NCT02865135
Date: 7/2016 (last updated 12/2016)
Regions: US; Northeast and Mid-Atlantic; Dana-Farber Cancer Institute, Boston, MA
This research study is studying a therapeutic vaccine, named DPX-E7, as a possible treatment for Human Papilloma Virus or HPV related head and neck, cervical or anal cancer (positive for HLA-A*02).
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (CheckMate358)
Trial Identifier: NCT02488759
Date: 6/2015 (last updated 4/2017)
Regions: Multi-region; Recruiting sites have contact information. Please contact the sites directly: firstname.lastname@example.org; Contact: First line of the email MUST contain NCT# and Site #
The purpose of this study to investigate the safety and effectiveness of Nivolumab, and Nivolumab combination therapy, to treat patients who have virus-associated tumors. Certain viruses have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drugs, in patients who have the types of tumors identified.
HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers, HESTIA
Trial Identifier: NCT02379520
Date: 2/2015 (last updated 2/2017)
Regions: US; South; Houston Methodist Hospital, Houston, Texas
The purpose of this study is to find the biggest dose of HPVSTs (special immune system cells) that is safe, to see how long they last in the body, to learn what the side effects are and to see if the HPVSTs will help people with HPV associated cancers. If the treatment with HPVST cells alone proves safe (Group A), additional group of patients (Group B) will receive Nivolumab in addition to HPVST cells in a lymphodepleted environment. Nivolumab is an antibody therapy that helps T cells control the tumor and it is FDA approved for the treatment of certain types of cancers, including Hodgkin's lymphoma. Lymphodepletion will decrease the level of circulating T cells prior to infusion of HPVST cells, thereby giving them room to expand. The purpose of this part of the study is to find out if TGF-beta resistant HPVST cells in combination with Nivolumab are safe, how long they last in the body and if they are more effective than HPVST cells alone in controlling the tumor.
Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies
Trial Identifier: NCT02241369
Date: 9/2014 (last updated 8/2016)
Regions: US; Northeast and Mid-Atlantic; University of Pennsylvania, Philadelphia, PA 19104 Contact: Alison Berry 215-662-2847 email@example.com Principal Investigator: Charu Aggarwal, MD
This is a Phase I, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3106 alone or in combination with INO-9012 DNA vaccines delivered by Electroporation to subjects with HPV6 associated aerodigestive precancerous lesions and malignancies.